CF Industries: A Long-Term Value Investing Analysis

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it growing a piece of an existing pie, or creating an entirely new market?4/10

  A

  The ceiling isn't low, but at its core this is "growing a piece of an existing pie," not "creating a new market" — and that pie is expanding at only a single-digit rate. Measured against Baillie's LTGG yardstick, CF isn't the kind of company that can conjure an entirely new demand curve out of thin air; it's fighting for better positioning within an already-mature, modestly growing global nitrogen fertilizer/ammonia market.

  Start with how big the pie is and how fast it's growing. Nitrogen fertilizer is a hard necessity — it must be reapplied every year, which gives long-term demand a solid floor; but that floor grows slowly. Per the IFA's Medium-Term Fertilizer Outlook 2025–2029, total global fertilizer use is projected to reach roughly 224 million tonnes of nutrients by 2029, up about 18 million tonnes from 2024, an annual growth rate of roughly 1%–2%; the same outlook, cited in the report, also puts global nitrogen demand rising from 166.6 million tonnes of N in 2024 to roughly 184.9 million tonnes of N by 2029 — about 9% cumulative growth over five years, or roughly 1.7% annually. In other words, this is a "certain but slow" mature market, not the kind of emerging market — like SaaS or EVs — where penetration jumps from single digits upward.

  More importantly, the pie is also set to be carved up by more supply over the next few years. The same IFA outlook projects global ammonia capacity growing roughly 10.5% by 2029 (from 195 to 216 million tonnes of N), with supply expanding faster than demand — meaning the industry balance is likely to loosen. That leaves CF little room to lift profitability simply because "the market is getting bigger"; it has to rely more on holding share from the left-most position on the cost curve.

  CF's positioning within this pie is genuinely strong: the report discloses that its eight North American manufacturing facilities together account for roughly 40%/41%/44%/19% of North American ammonia/urea/UAN/ammonium nitrate capacity, making it one of the largest ammonia production networks in the world. But "high share in a slow-growth market" and "high ceiling" are two different things — already having high share actually means the marginal room to keep growing by taking more share is narrowing.

  The one thing that might count as "half a new market" is low-carbon/clean ammonia. The report treats the Blue Point low-carbon ammonia project (facility cost roughly $3.7 billion) as a potential new profit pool; in theory, clean ammonia could open incremental demand in shipping fuel, power-grid peaking, and hydrogen-carrier applications. But today this line is still an "option," not a "market that's already running": the size of demand and whether a premium can hold both still need time to prove out, and the report itself lists this among its biggest uncertainties. So, honestly — CF's ceiling supports a good asset that can exist solidly for many years, but not the kind of growth stock that Baillie chases, one that "exponentially opens up an entirely new market."

  Jun 11, 2026
• QCan its revenue at least double over the next five years? Is growth driven mainly by volume, price, or new businesses?3/10

  A

  Almost impossible. For CF's revenue to double over the next five years would require another 2022-scale spike in nitrogen fertilizer prices — that's a cyclical windfall, not sustainable structural growth; on a neutral view, revenue five years from now is most likely to be at roughly today's level or even lower. Baillie's ideal "revenue doubles in five years" is powered by volume-driven or new-business-driven compounding, while CF's revenue equation is "tonnage × global market price," with volume barely growing and price set by the cycle — this is exactly the kind of business where doubling is hardest.

  Start with the base and current state. CF's full-year 2025 net sales were $7.084 billion (up from roughly $5.94 billion in 2024), with net income attributable to CF of $1.455 billion and a gross margin of 38.5%. Doubling in five years means revenue would need to reach roughly $14 billion by around 2030 — and the only year CF has ever touched that scale historically was 2022 (the report discloses $11.19 billion of revenue that year), driven by an extreme environment of European natural gas prices spiking after the Russia-Ukraine conflict and a collapse in global ammonia supply. Treating that kind of once-in-a-century supply shock as a five-year planning baseline doesn't fit Baillie's discipline that "even bullish upside needs realistic conditions."

  Now break this into the three engines — volume, price, and new business:

  • Volume: essentially flat. CF is an operator of existing capacity; adding a major new plant takes years and is extremely capital-intensive. Blue Point won't come online until around 2029, and 60% of the capital for the core facility is being funded by the partner, with CF holding only a 40% interest. In the near term (2026 guidance), the company's existing-operations capex is only about $550 million — not a major capacity expansion. The report also notes that the Yazoo City plant is not expected to be fully back online until roughly the end of Q4 2026 following its Q4 2025 incident, so near-term volume is even under pressure.

  • Price: the main swing factor for revenue, but the bias is neutral-to-down. The IFA expects global ammonia capacity to grow roughly 10.5% from 2025 to 2029, outpacing demand, loosening the industry balance; the report accordingly judges that the earnings center of gravity is more likely to move down than up. Current nitrogen fertilizer tightness (China's export restrictions, Middle East tensions) is lifting prices today, but that's a short-term supply shock that shouldn't be extrapolated.

  • New business: low-carbon ammonia is the only incremental candidate, but its contribution to revenue before 2030 is limited in scale, and the premium has not yet been proven.

  Q1 2026 net sales of $1.986 billion (up 19.4% year over year) is genuinely impressive, but that's a price-driven cycle-peak reading and can't be linearly annualized. Taken together, doubling in five years is a low-probability event that "requires an extreme cycle to recur"; the more realistic neutral picture is revenue fluctuating in a $6 billion to $8 billion range with the cycle, not necessarily higher in five years than today. The honest answer to this question for CF is "no."

  Jun 11, 2026
• QFive years from now, what takes over as the next growth engine? Does this "second curve" exist today?4/10

  A

  There's only one candidate for a second curve — low-carbon/clean ammonia (Blue Point). Today it "exists in the form of a construction site," but it is far from becoming a growth engine that can take over, and looks more like an option that needs years to prove out. Baillie's question "what takes over in five years" ideally wants a company that already has an accelerating new curve inside it that can grow independently; CF's reality is that its traditional nitrogen fertilizer business is itself a slow-growth, mature book, while its only new curve is still in a capital-investment phase with an unproven business model.

  The ceiling on the first curve is exactly what makes the question "must there be a second curve" so pointed. Traditional ammonia/urea/UAN is a global commodity, with demand growing roughly 1.7% annually (per the IFA's 2025–2029 outlook cited in the report), and supply growth is expected to outpace demand over the next few years, loosening the industry. Relying on the legacy business alone, CF will most likely still be a cyclical cash cow of roughly today's scale five years from now — stable, but not growing.

  Second-curve candidate: Blue Point low-carbon ammonia. The report discloses that the project's facility cost is roughly $3.7 billion, with another roughly $550 million needed for scalable infrastructure; in 2026 the company's consolidated capex is expected to be roughly $1.3 billion, of which about $600 million goes to Blue Point joint-venture construction and about $150 million to supporting infrastructure (CF's full-year results/guidance disclosure confirms roughly $1.3 billion of 2026 capex, split into about $550 million for existing operations and about $600 million for the Blue Point joint venture). In theory, clean ammonia can connect to new demand pools such as shipping fuel, hydrogen carriers, and power generation; if it commands a real premium, both the moat and the profit pool could widen.

  But today it's "not an engine, it's a bet," for three reasons:

  1. The timeline is distant: the facility isn't expected to come online until around 2029, so its substantive contribution to profit within five years is limited — it's not really "taking over" anything.
  2. The model is unproven: whether the low-carbon premium can hold, and whether customers are willing to pay for the green attribute, is explicitly listed by the report as one of the biggest uncertainties; management itself acknowledges that customers look at delivered price first and low-carbon attributes second.
  3. Cash flow is a net outflow, not an inflow: the report repeatedly emphasizes that the company's capital allocation is shifting from "distributing cash" to "consuming cash" — right now the second curve eats cash rather than generating it; the classic large-chemical-project risk of "greenlit at the cycle top, coming online at the cycle bottom" is genuinely present here.

  Honest conclusion: CF has a second curve drawn on blueprints and under construction, and its direction (decarbonization) is on the right side of the long-term trend, but today it can neither carry revenue, nor has its return been proven above the cost of capital. Treating it as an "already-existing growth engine" would overrate this company — it's closer to a call option that still needs 3 to 5 years before a verdict can be reached.

  Jun 11, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?5/10

  A

  The core advantage is a cost-leadership position built from "low-cost North American natural gas + scaled ammonia plants + high asset utilization" — this is a real moat, but it's a heavy-asset entry barrier, not a wide brand- or network-type moat; over the next three to five years it will most likely "hold steady with a slight improvement, but not widen meaningfully." Baillie cares about a moat's "direction and sustainability"; CF's moat direction is neutral and its width is limited — honestly, it can support a good business, but not a great growth stock.

  Where the moat comes from (strengths):

  • Cost advantage — this is the hardest one. All of CF's ammonia plants are in North America, giving it access to a low-cost, relatively stable natural gas network. The contrast is compelling: of Yara's roughly 8.5 million tonnes of global ammonia capacity, about 4.9 million tonnes is in Europe (roughly 58%, consistent with the report's citation of "roughly 56% in Europe" from Yara's credit report); under high European gas prices, Yara was once forced to cut roughly 35% of its European capacity. CF sits at the far left of the global cost curve and benefits structurally from that position.
  • Operating efficiency — CF's own "soft moat." The report cites the 2026 proxy statement showing CF's five-year average long-term asset utilization has run roughly 10 percentage points above the North American competitor average; that translates into real profitability: full-year 2025 gross margin of 38.5%, Q1 2026 gross margin of 37.6% — quite solid for a commodity producer.
  • Scale and logistics: one of the largest ammonia producers in the world, with 40 distribution facilities, access to the 2,000-mile Sunoco ammonia pipeline, and proximity to the U.S. Corn Belt, lowering delivered costs and improving flow flexibility.

  The ceiling on the moat (weaknesses, to be honest):

  • Weak brand, low switching costs, almost no network effects. The report states plainly that nitrogen fertilizer isn't Coca-Cola — customers mainly look at delivered price. What CF holds is "a right to retain profit under a low-cost structure," not traditional pricing power. Replicating its North American asset network would take years and several billion dollars, but "selling fertilizer" itself isn't hard.

  Will it widen or narrow over three to five years? My judgment: "slightly wider, not meaningfully":

  • Forces toward widening: if low-carbon ammonia commands a real premium, it could add a layer of intangible-asset barrier; if North American shale gas's long-term cost advantage persists, the moat's foundation stays solid.
  • Forces toward narrowing: the report's second risk category explicitly notes that if the North America-to-Europe gas-price spread narrows, CF's "most important moat gets thinner"; meanwhile, the IFA expects industry supply to loosen, which would erode excess margins.

  Net judgment: this is a moat that is "real, quantifiable, but capped" — it lets CF survive cycle troughs better than high-cost competitors, but it can't upgrade this global commodity business into a highly predictable compounding machine. Direction is stable, width is limited.

  Jun 11, 2026
• QIf its core business were disrupted, does it have the genes for self-reinvention? How does it handle mistakes and bad news?4/10

  A

  "The gene for self-reinvention when disrupted" is the weakest link for a heavy-asset cyclical leader like CF — it excels at pushing cost and efficiency to the extreme within an established lane, but lacks the flexibility to tear itself down and start over; how it handles mistakes and bad news, on the other hand, leans honest and disciplined, which is a point in its favor. What this Baillie chain question is really asking is: if the core business (selling ammonia/nitrogen fertilizer) were structurally disrupted, does the company have the regenerative capacity to "live a new life"? For CF, the answer is: slow to turn, but quick to admit fault.

  Start with the self-reinvention gene — leaning weak, and that's the honest judgment. All of CF's value is anchored in several billion dollars of fixed assets: eight North American manufacturing facilities, 2,000 miles of pipeline access, and 40 distribution points. This asset structure means it can't pivot quickly the way an asset-light platform can — a single ammonia plant is a decade-plus, multi-billion-dollar commitment, and Donaldsonville alone accounted for roughly 40% of the company's ammonia capacity in 2025 (per the report); high concentration also means a small turning radius. There are really two scenarios that could disrupt its core: (1) long-term de-chemicalization/precision agriculture on the farming side sharply reducing nitrogen demand; (2) green hydrogen/electrolysis routes causing traditional natural-gas-based ammonia to lose its cost advantage. Facing the first, CF has almost no answer; facing the second, its response is precisely Blue Point low-carbon ammonia — which shows management is genuinely "reinventing itself in the direction of decarbonization," but this path is a gradual upgrade along its existing ammonia core business, not the kind of regeneration where "the core gets disrupted and it starts a completely new venture." So the gene is "evolutionary," not "transformational."

  Now, how it handles mistakes and bad news — this is a clear point in CF's favor.

  • Bad news isn't hidden. The report shows the company disclosing negative information directly in multiple places: after the Yazoo City incident in Q4 2025, guidance clearly stated recovery wouldn't come until roughly the end of Q4 2026; the Q1 2026 filing candidly discloses litigation alleging anticompetitive conduct dating back to 2020/2021 (plaintiffs seeking treble damages, punitive damages, and injunctive relief), and honestly states it "currently cannot estimate a range of potential loss," with no glossing over.
  • No reckless moves at the top of the cycle. Historical behavior shows discipline: the report records that CF did not lever up recklessly for a big acquisition at the 2022 cycle peak — instead it repaid $500 million of debt and repurchased shares heavily; Q1 2026 explicitly called out roughly $170 million of litigation-settlement gains and flagged that it shouldn't be annualized — this kind of "proactively filtering the noise out of its own earnings" disclosure attitude is exactly a healthy error-correction culture.
  • Error-correction mechanisms are built into governance: the report notes the company has a clawback policy and an insider-trading policy prohibiting hedging and pledging of company stock.

  Net judgment: CF does well on "admitting mistakes, not deceiving itself, not overextending in good times," which keeps it from making fatal errors through the cycle; but if its core ammonia business were structurally disrupted, its heavy balance-sheet structure and highly concentrated plants leave it lacking the kind of "tear it down and start over" regenerative resilience Baillie values. Honest and disciplined, but not flexible.

  Jun 11, 2026
• QDoes management (especially the founder) have a long-term horizon and deep alignment of interests with the company? Is it willing to sacrifice current profit for returns five to ten years out?4/10

  A

  Long-term vision — yes; deep alignment of interests with the company — clearly lacking. This is the point in CF's governance assessment that most deserves a discount. Baillie favors an "ownership" structure where founders/management hold real skin in the game and are willing to sacrifice today's profit for returns five to ten years out; CF is a professionally managed, well-institutionalized company with decent discipline, but management has not put its own wealth on the line in the stock.

  Start with "insufficient alignment" — the hard numbers speak. The report discloses that as of March 5, 2026, all directors and executive officers together held 781,578 shares, less than 1% of shares outstanding. Set against today's numbers, this is even more striking — CF's diluted weighted-average share count is roughly 154.5 million, with a market cap of roughly $16.8 billion (at the current price of ~$109); 781,578 shares corresponds to only about $85 million in value, spread across the entire board and executive team — no single individual's wealth is on a scale where it "rises and falls together" with the stock. CF also has no founder/controlling-shareholder layer — it's a classic dispersed-ownership, professionally managed company. This means alignment of interests rests mainly on compensation design, ownership guidelines, and clawback policy, rather than management's own large stake. Under the Baillie framework, this is a structural weakness.

  Now, "long-term vision" — CF holds up here.

  • Succession is internal continuity, not an outside star hire. The report notes that Christopher D. Bohn was promoted from COO to President and CEO starting in January 2026, and the board maintains a separate independent chair and CEO. For a cyclical manufacturer, this kind of smooth transition is generally more reliable than parachuting in an outside star.
  • Capital allocation reflects long-cycle discipline. The company hasn't pursued reckless M&A at the top of the cycle, instead continuing to deleverage, buy back shares, and pay dividends: full-year 2025 it repurchased 16.6 million shares for $1.34 billion, shrinking shares outstanding by roughly 10% versus year-end 2024, and paid $326 million in dividends — prioritizing per-share intrinsic value is a sign of long-term thinking.
  • Is it willing to sacrifice the present for five to ten years out? This is the real test right now. The Blue Point low-carbon ammonia project (facility cost roughly $3.7 billion) is exactly a bet that "sacrifices cash today, wagers on ten years from now" — management is indeed making that bet, but it's a double-edged sword: what the report worries about is precisely that the company might "overinvest at the top of the cycle for a growth narrative and dilute shareholder returns." So "willingness to sacrifice the present" is both evidence of long-term vision and the biggest risk point.

  Net judgment: management is rational, disciplined, and has a long horizon, and the governance framework is sound (independent chair, clawback, hedging/pledging bans); but on "deep alignment," the thing Baillie values most, CF is substantively absent — there's no founder, and executive ownership is under 1%. This company is trustworthy, but on the strength of its systems, not because "the boss has his own wealth on the line."

  Jun 11, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not dependent on harming society or courting regulatory backlash?5/10

  A

  If CF disappeared tomorrow, customers would be badly inconvenienced in the short run, but they wouldn't "miss the brand" — its indispensability comes from the role of "low-cost North American ammonia capacity," not from CF as a company; its growth model is broadly sustainable and doesn't rely on harming society, though the ammonia industry inherently carries a three-way regulatory tension around safety, environment, and antitrust. This Baillie question requires a dual test: (1) how indispensable is it; (2) is growth achieved by harming society or inviting regulatory backlash. CF scores "role is important, but the entity is replaceable" on the first, and "basically clean, but with an unresolved litigation tail" on the second.

  First — indispensability: it's "the capacity that matters," not "CF that matters." Nitrogen fertilizer is a physical necessity for food security and must be reapplied every year; CF is one of the largest ammonia/nitrogen suppliers in North America (the report discloses its North American facilities account for roughly 40%/41%/44% of North American ammonia/urea/UAN capacity). If it vanished overnight, North America's growing season would immediately face a supply gap and a spike in delivered prices — that short-term pain is real. But what customers would "miss" is that low-cost tonnage, not the CF brand: the report repeatedly emphasizes that the product is a global commodity, customers care mainly about delivered price, and switching costs are low. The gap would gradually be filled by imports, Nutrien, CVR, and European capacity (even if higher-cost). Contrast this with Coca-Cola-style "consumers would be heartbroken if it disappeared" — with CF, "if it disappeared, the supply chain would just go find new supply." So its indispensability is medium and structural, not emotional or lock-in-based.

  Second — is growth sustainable and not dependent on harming society or regulation:

  • Positive: nitrogen fertilizer supports global food output, so the underlying social value is positive; CF's growth narrative (low-carbon/clean ammonia, Blue Point) is directionally about "reducing, not increasing" its environmental footprint, aligned with the broader decarbonization trend rather than growth achieved by drawing down the environment.
  • Regulatory/social tensions to watch: (1) Antitrust — the report and the Q1 2026 disclosure show the company facing litigation alleging anticompetitive conduct dating back to 2020/2021, with plaintiffs seeking treble damages and injunctive relief, and the company still unable to estimate a loss range. This is exactly the regulatory soft spot of a "high-share industry" and needs ongoing monitoring. (2) Safety/environment — ammonia is a high-hazard chemical, and the Q4 2025 Yazoo City incident is a case in point; safety and environmental thresholds are both a barrier and a potential drag on profitability (the report explicitly notes that regulation "can also erode profitability"). (3) The source of current profit — the report honestly points out that part of the elevated 2025–2026 earnings benefits from China's export restrictions and Middle East tensions pushing up prices; profit driven by geopolitical disruption like this isn't "sustainable good growth," and is actually a risk for new buyers.

  Net judgment: CF provides something society genuinely needs, and the underlying character of its growth is clean, even directionally positive (decarbonization); but its "indispensability" is a replaceable capacity role, and its high market share brings real antitrust and safety-regulatory tension — the unresolved litigation is the most concrete deduction on this question.

  Jun 11, 2026
• QWhat are this business's unit economics (gross margin, incremental returns) like? Does it get better or worse as it scales? Where does the cash it earns go?5/10

  A

  Unit economics look quite attractive in "good years," and incremental returns are decent too, but they swing heavily with the cycle and gas prices — this isn't the kind of "bigger is always better" compounding flywheel. What scale mainly delivers is steady-state cost-curve leadership, not a persistent rise in marginal margins. Cash earned in the past has gone mainly to buybacks, dividends, and deleveraging; now it's being heavily redirected into Blue Point. Baillie wants to look at three things: unit-economics quality, direction of scaling, and where the cash goes. CF is cyclical on quality, neutral on direction, and now shifting from "returning cash" to "spending cash" on where the cash goes.

  Unit economics: quality is genuinely solid, but carries a cyclical imprint.

  • Gross margin is high and currently near a peak: full-year 2025 gross profit was $2.724 billion, a 38.5% gross margin, and Q1 2026 gross margin was 37.6% — very strong profitability for a commodity producer, underpinned by low-cost North American gas plus roughly 10 percentage points of asset-utilization advantage over peers (per the report).
  • Accounting profit converts solidly into cash: full-year 2025 operating cash flow was $2.752 billion and free cash flow was $1.789 billion, with free cash flow covering net income well; the report also runs a more conservative Owner Earnings estimate, centered around roughly $1.6 billion a year.
  • But volatility is the underlying character: the report's six-year table shows revenue falling from $11.19 billion in 2022 to $5.94 billion in 2024, and net income attributable to CF falling from $3.346 billion to $1.218 billion — with the same set of plants, unit economics can swing two-to-threefold across the cycle. Natural gas accounted for roughly 34% of total production costs in 2025, and every $1/MMBtu move changes per-ton ammonia cost by roughly $32 (per the report), which means margins aren't something the company can unilaterally control.

  Does it get better or worse as scale grows? — mainly "steady-state leadership," not a "compounding flywheel." Ammonia/nitrogen fertilizer has no network effects or data flywheel; the value of scale lies in spreading fixed costs, locking in the best gas sources and logistics, and maintaining high utilization, which lets it survive cycle troughs better than high-cost competitors (compare Yara, with roughly 58% of capacity in high-gas-price Europe, once forced to cut roughly 35%). But doubling in size again wouldn't systematically raise per-ton marginal margins — this is the essential difference from SaaS or platform-type businesses. Incremental returns on capital are "good but clearly cycle-affected," which is exactly how the report's own checklist judges it.

  Where does the cash go? — shifting from "distribution" to "reinvestment," which is the key variable.

  • Past (mostly distribution, and done well): 2025 buybacks of 16.6 million shares/$1.34 billion, shrinking shares outstanding by roughly 10%, with $326 million paid in dividends; the report estimates the 2024/2025 average buyback price at roughly around $80, well below the current ~$109 — value-accretive buybacks.
  • Now (mostly reinvestment, return unproven): 2026 capex guidance is roughly $1.3 billion, with the bulk shifting to Blue Point (facility cost roughly $3.7 billion). The report's core worry is precisely whether this turns "an excellent cash-buyback machine" into "a low-return chemical project at the top of the cycle," dragging down overall incremental returns.

  Net judgment: in good years, CF's unit economics make it a "high-margin, strong-cash-generating" quality cash cow, but it's cyclical rather than compounding — scale delivers steady-state cost leadership, not rising marginal margins; the destination of cash is now at an inflection point from "returning money to shareholders" to "spending it itself," and Blue Point's return will determine whether the incremental economics of this business get better or worse going forward.

  Jun 11, 2026
• QWhat conditions would all have to hold simultaneously for it to rise 5x in ten years? Are those conditions realistic? What expectations does today's stock price imply?3/10

  A

  A 5x gain over ten years is almost unrealistic for CF — it would require three low-probability things to happen simultaneously: "permanently elevated cycle-peak earnings + a big expansion in the valuation multiple + Blue Point delivering high returns"; and today's roughly $109 stock price doesn't imply a pessimistic view at all — it's actually pricing in a "neutral, decent" reasonable return, without giving new buyers an adequate margin of safety. Baillie encourages blue-sky thinking, but equally demands an honest breakdown of "what must hold simultaneously, and what the current price already assumes." For CF, the honest answer here is "hard on the math, not cheap on the price."

  Start with the math for 5x. The current price is roughly $109.40 (2026-06-10, down about 10% from the $121.70 price on the report's writing date of 2026-05-22), with a market cap of roughly $16.8 billion. A 5x gain over ten years means the stock reaching roughly $547, a market cap of roughly $84 billion, or roughly 17.5% annualized. Supporting that market cap requires the following conditions to hold simultaneously:

  1. Owner Earnings must double and stay there permanently. The report's central Owner Earnings estimate is roughly $1.6 billion a year; a 5x market cap roughly requires pushing sustainable earnings above $3 billion and having the market treat it as permanent. But that earnings level is close to the 2022 cycle peak (net income attributable to CF of $3.346 billion that year) — treating a once-in-a-century supply shock as the new normal isn't realistic.
  2. The valuation multiple must not compress — it must expand. CF's 2025 EPS was $8.97, and the current price implies a trailing P/E of roughly 12x; a cyclical stock at peak earnings should logically get a lower multiple. Getting to 5x would require the market to instead award commodity-chemical stocks an even higher multiple, which runs against the normal valuation pattern for cyclicals.
  3. Blue Point must deliver as a high-return new profit pool, with low-carbon ammonia commanding a real premium and capex not overrunning — the report lists this among its biggest uncertainties.
  4. Industry supply must not loosen as the IFA expects. But the IFA projects global ammonia capacity growing roughly 10.5% from 2025 to 2029, outpacing demand — exactly the opposite direction.

  None of these four conditions is easy, and the joint probability of all four holding at once is low. That's why, honestly: CF is not a "ten years, five times" candidate in the Baillie sense — it's more like a quality cyclical asset that "earns a reasonable return across one full cycle." Even the report's own optimistic annualized return is only 12%–15%, or roughly 3x–4x over ten years — short of the 5x bar.

  What does today's $109 imply about expectations? — "neutral, fair," not "cheap." The report gives a conservative intrinsic value of $75–95, a fair intrinsic value of $105–135, and an optimistic range of $160–190; the current price of ~$109 sits near the lower end of the fair range, having pulled back from the report's $121.70 at the time of writing to a level closer to the fair-value midpoint. In other words, the market's pricing implies a "mid-cycle, decent" long-term return — the report judges that the neutral-scenario annualized return of roughly 8%–11% is adequate but not meaningfully excess; the conservative scenario, at just 2%–5%, isn't compelling. The market hasn't "given up" on CF — quite the opposite, it has fairly priced in both its cost advantage and the current industry tightness. The margin of safety (the report requires at least a 25%–30% discount for cyclicals, with an ideal buy range of $85–100) is still insufficient at ~$109.

  Net judgment: the realism of all four conditions needed for 5x is low, and their joint probability is small; the current price implies fair, not undervalued, expectations. CF's biggest trap today isn't "no visible upside" — it's "a good company at a price that isn't cheap enough."

  Jun 11, 2026
• QWhy hasn't the market recognized all this yet? Does it not understand it, not respect it, or not see far enough? What would become the "narrative inflection point"?3/10

  A

  The market reads CF quite clearly, and there's no "misreading" here — its neutral pricing at roughly 12x P/E is exactly a fair recognition of a business that is "high-quality but cyclical, cost-leading but without pricing power." There's neither a "market doesn't understand it" perception-gap windfall here, nor obvious mispricing to the downside; what will actually become the narrative inflection point is whether time proves or disproves "whether current earnings are mid-cycle or high-cycle." What this Baillie question wants to find is an undervaluation opportunity caused by the market "not understanding it / underrating it / not seeing far enough"; for CF, the honest conclusion is — the market sees it clearly, and largely sees it correctly; there's no meaningful positive perception gap.

  Why say it "hasn't been overlooked":

  • Valuation already fully reflects the advantages. CF's current price is roughly $109.40 (2026-06-10, down about 10% from $121.70 on the report's writing date), implying a trailing P/E of roughly 12x on 2025 EPS of $8.97 and an EV/EBITDA of just over 7x. The report judges that "a roughly 11x–12x earnings multiple already prices in most of the North American cost advantage and the current industry tightness" — that's not a bubble, but it's certainly not a buried cigar butt either. The market clearly knows CF is a low-cost North American leader.
  • Coverage is thorough and information is transparent. CF is a large-cap index constituent with dense institutional coverage and clear disclosure (full-year 2025/Q1 2026 data is complete, and the Yazoo City incident, antitrust litigation, and Blue Point capex are all public). This isn't a small-cap stock hiding in a corner that nobody covers — the "nobody sees it" rationale for undervaluation doesn't hold.
  • The 52-week range itself shows the market actively pricing the cycle. Over the past year the stock has swung sharply between $75.42 and $141.96, with a notable pullback recently — the market isn't failing to watch CF, it's continuously and forcefully voting on whether this round of earnings is sustainable.

  So where might the market be "not seeing far enough"? (The only potential perception gap, though its direction is uncertain) Where real disagreement exists — and where it's hardest to see far — is: how much of today's elevated earnings is sustainable "mid-cycle profit," and how much is merely "high-cycle profit" lifted by China's export restrictions and Middle East tensions. The report flags this as its most fragile valuation assumption.

  • If the bears are right (this is a high-cycle top), the current price — "high-cycle profit × a seemingly cheap multiple" — is actually expensive;
  • If the bulls are right (North American cost advantage + industry discipline structurally lift the earnings center of gravity), then the current price is fair to slightly low. The neutral multiple the market currently assigns is exactly evidence that it isn't betting on either extreme — which is itself evidence that "pricing is already fairly efficient," not a signal of undervaluation.

  What would become the narrative inflection point?

  • Upside inflection points: (1) Blue Point low-carbon ammonia lands real, sizable green-premium orders, proving out the second curve; (2) the North America-to-Europe/global natural-gas cost spread widens structurally, cementing CF's cost moat; (3) industry supply discipline beats expectations, the overcapacity the IFA worries about doesn't materialize, and the earnings level is re-rated as "mid-cycle" rather than "high-cycle."
  • Downside inflection points: (1) the IFA's warning of roughly 10.5% ammonia capacity growth from 2025 to 2029, outpacing demand, materializes, prices retreat, and the earnings level shifts down; (2) China's export restrictions are lifted and Middle East disruptions ease, the short-term premium fades, and the market concludes this round was a high-cycle top; (3) Blue Point overruns its budget or the low-carbon premium fails to materialize, or the unresolved antitrust litigation results in a payout.

  Net judgment: CF isn't a case of "the market doesn't understand it, so it's undervalued" — it's thoroughly researched and fairly, neutrally priced. The honest answer for CF on this question is: the inflection point isn't about "when the market wakes up to how undervalued it is," but about "whether time proves current earnings to be mid-cycle (bullish) or disproves them as a high-cycle top (bearish)"; until that's resolved, the current price of ~$109 offers a fair return, not a perception-gap windfall.

  Jun 11, 2026